Cysteine engineered fibronectin type III domain binding molecules
Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
1. An engineered fibronectin type III (FN3) domain peptide comprising an amino acid residue substituted with a cysteine residue at an amino acid position selected from the group consisting of residues 6, 8, 10, 14, 15, 20, 45, 48, 53, 54, 59, 64, and 88 of the FN3 domain, wherein the amino acid positions of the residues of the FN3 domain correspond to the amino acid positions of SEQ ID NO: 1, and wherein the FN3 domain peptide comprises a peptide having at least 87% identity to a peptide comprising the amino acid sequence of SEQ ID NO: 27.
2. The engineered FN3 domain peptide of claim 1 , further comprising a half-life extending moiety.
3. The engineered FN3 domain peptide of claim 2 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), or at least a portion of an Fc region of an immunoglobulin.
4. The engineered FN3 domain peptide of claim 1 , wherein the engineered FN3 domain peptide has an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 189, SEQ ID NO: 227, SEQ ID NO: 190, SEQ ID NO: 228, SEQ ID NO: 192, SEQ ID NO: 230, SEQ ID NO: 193, SEQ ID NO: 231, SEQ ID NO: 195, SEQ ID NO: 233, SEQ ID NO: 201, SEQ ID NO: 239, SEQ ID NO: 203, SEQ ID NO: 241, SEQ ID NO: 205, SEQ ID NO: 243, SEQ ID NO: 206, SEQ ID NO: 244, SEQ ID NO: 209, and SEQ ID NO: 247.
5. An engineered fibronectin type III (FN3) domain peptide comprising an amino acid residue substituted with a cysteine residue at an amino acid position selected from the group consisting of residues 11, 16, 30, 34, 38, 40, 41, 47, 60, 62, 70, 83, 84, and 85 of the FN3 domain, wherein the amino acid positions of the residues of the FN3 domain correspond to the amino acid positions of SEQ ID NO: 1, and wherein the FN3 domain peptide comprises a peptide having at least 87% identity to a peptide comprising the amino acid sequence of SEQ ID NO: 27.
6. The engineered FN3 domain peptide of claim 5 , further comprising a half-life extending moiety.
7. The engineered FN3 domain peptide of claim 6 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), or at least a portion of an Fc region of an immunoglobulin.
8. The engineered FN3 domain peptide of claim 5 , wherein the engineered FN3 domain peptide has an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 191, SEQ ID NO: 229, SEQ ID NO: 194, SEQ ID NO:232, SEQ ID NO:196, SEQ ID NO: 234, SEQ ID NO: 197, SEQ ID NO: 235, SEQ ID NO: 198, SEQ ID NO: 236, SEQ ID NO: 199, SEQ ID NO: 237, SEQ ID NO: 200, SEQ ID NO: 238, SEQ ID NO: 202, SEQ ID NO: 240, SEQ ID NO: 207, SEQ ID NO: 245, SEQ ID NO: 208, SEQ ID NO: 246, SEQ ID NO: 211, SEQ ID NO: 249, SEQ ID NO: 212, SEQ ID NO: 250, SEQ ID NO: 213, SEQ ID NO: 251, SEQ ID NO: 214, and SEQ ID NO: 252.